Company / Depreciation & Amortization
Kymera Therapeutics, Inc. Depreciation & Amortization History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$8.3M
FY2025
5-year range
$825.0K / $8.3M
FY2021-FY2025
Trend
+12.7%
vs FY2024
Sector context
#69 of 163
Health Care
What the data says
At $8M, Kymera Therapeutics, Inc.'s depreciation & amortization ranks #95 of 163 in the Health Care sector. Depreciation & Amortization has increased for 4 consecutive years, from $825,000 in FY2021 to $8M in FY2025.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +58.7%.
Increased from $4M to $8M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +40.8%
- 5-Year CAGR
- +58.7%
- 10-Year CAGR
- -
Sector benchmark
#95 of 163 in Health CareTop 58% of 163This company $8.3M Sector average $219.4M
▼
-96.2% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +58.7%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 12.7% year-over-year.
- Ranks #69 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.3M | +12.7% |
| FY2024 | $7.4M | +106.8% |
| FY2023 | $3.6M | +19.8% |
| FY2022 | $3.0M | +260.8% |
| FY2021 | $825.0K | +0.0% |
| FY2020 | $825.0K | +0.0% |
| FY2019 | $825.0K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026